c-RET
c-RET inhibitors target the RET (Rearranged during Transfection) proto-oncogene, which encodes a receptor tyrosine kinase involved in cell growth, differentiation, and survival. Abnormal activation of RET signaling can lead to uncontrolled cell proliferation and resistance to apoptosis, contributing to the development of cancers such as medullary thyroid carcinoma and non-small cell lung cancer. Inhibiting c-RET can induce apoptosis in cancer cells and is a promising approach in targeted cancer therapy. At CymitQuimica, we offer a variety of high-quality c-RET inhibitors to support your research in oncology, signal transduction, and apoptosis.
Found 61 products for "c-RET".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
RET-IN-23
CAS:RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.Formula:C28H28FN11Purity:97.46%Color and Shape:SolidMolecular weight:537.59TG-89
CAS:TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFormula:C26H34N6O3SPurity:98.68%Color and Shape:SolidMolecular weight:510.65Pz-1
CAS:Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.Formula:C26H26N6O2Purity:99.89%Color and Shape:White SolidMolecular weight:454.52RET-IN-13
CAS:RET-IN-13: potent quinoline RET inhibitor; IC50 = 0.5 nM (WT), 0.9 nM (V804M); potential for RET-related tumor/intestinal disease research.Formula:C32H33F4N5O3Color and Shape:SolidMolecular weight:611.63NSC194598
CAS:NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.Formula:C20H19N3OColor and Shape:SolidMolecular weight:317.38FHND5071
CAS:FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumorFormula:C30H30D3N9OColor and Shape:SolidMolecular weight:538.66FLT3/ITD-IN-4
CAS:FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Formula:C25H22N4O5Color and Shape:SolidMolecular weight:458.47RET-IN-5
CAS:RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).Formula:C29H26FN9OColor and Shape:SolidMolecular weight:535.57RET-IN-24
CAS:RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].Formula:C27H26F2N8OColor and Shape:SolidMolecular weight:516.55RET-IN-25
CAS:RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximalFormula:C22H17N3O5SColor and Shape:SolidMolecular weight:435.45RET-IN-17
CAS:RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.Formula:C27H28F4N4O4Color and Shape:SolidMolecular weight:548.53RET-IN-9
CAS:RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.Formula:C26H27N9OColor and Shape:SolidMolecular weight:481.55LRRK2-IN-17
CAS:LRRK2-IN-17 is an orally active LRRK2 inhibitor with IC50 values of 3.5 nM for WT and 3.3 nM for G2019S, and it also inhibits RET kinase with an IC50 of 59 nM. LRRK2-IN-17 is utilized in research related to cancer and Parkinson's disease (PD).Formula:C18H18N8Color and Shape:SolidMolecular weight:346.39FHND5071 (1H)
CAS:FHND5071 (1H) is a selective inhibitor of RET (rearranged during transfection) tyrosine kinase. It shows potential for research applications in RET-driven cancers, such as thyroid and lung cancer.Formula:C30H33N9OColor and Shape:SolidMolecular weight:535.64TAS05567
CAS:TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Formula:C21H29N9O2Purity:98%Color and Shape:SolidMolecular weight:439.51RET-IN-30
CAS:RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. It is capable of inhibiting the proliferation of A549 cells and demonstrates antitumor properties.Formula:C26H26FN5OColor and Shape:SolidMolecular weight:443.52RET-IN-10
CAS:RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).Formula:C29H28N8OSColor and Shape:SolidMolecular weight:536.65RET-IN-7
CAS:RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice throughFormula:C22H24ClFN6O2Color and Shape:SolidMolecular weight:458.92RET-IN-1
CAS:RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).Formula:C29H31N9O3Purity:98%Color and Shape:SolidMolecular weight:553.61WF-47-JS03
WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.Formula:C30H38N6O2Color and Shape:SolidMolecular weight:514.66
